Last reviewed · How we verify
Pangramin Plus D. pteronyssinus 100%
Pangramin Plus D. pteronyssinus 100% is a Biologic drug developed by ALK-Abelló A/S. It is currently FDA-approved.
Pangramin Plus D. pteronyssinus 100% is a marketed product by ALK-Abelló A/S, currently positioned in the allergen immunotherapy market. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of reported revenue data, which may indicate limited market penetration or sales challenges.
At a glance
| Generic name | Pangramin Plus D. pteronyssinus 100% |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis (PHASE2)
- Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pangramin Plus D. pteronyssinus 100% CI brief — competitive landscape report
- Pangramin Plus D. pteronyssinus 100% updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI
Frequently asked questions about Pangramin Plus D. pteronyssinus 100%
What is Pangramin Plus D. pteronyssinus 100%?
Who makes Pangramin Plus D. pteronyssinus 100%?
What development phase is Pangramin Plus D. pteronyssinus 100% in?
Related
- Manufacturer: ALK-Abelló A/S — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing